Vitamin B12 shows promise in preventing chemo side effect
NCT ID NCT05165069
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether mecobalamin (a form of vitamin B12) can prevent severe hand-foot syndrome in early breast cancer patients taking capecitabine. About 234 women will receive either mecobalamin or a placebo. The goal is to see if the vitamin reduces painful skin reactions on hands and feet, helping patients stay on treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, 510120, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a diabetes drug slow breast cancer growth?
- Young breast cancer patients share views on fertility risks in new survey
- Older women with Low-Risk breast cancer may avoid unnecessary surgery
- Could a pill replace chemo for some breast cancer patients?
- Ice plant cream may shield cancer patients from chemo side effect
- Scientists Re-Analyze old samples to unlock secrets of HER2-Low breast cancer